

Rima Kaddurah-Daouk

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8070993/rima-kaddurah-daouk-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92
papers

7,535
citations

46
h-index

86
g-index

94
ext. papers

8,676
ext. citations

7.4
avg, IF

5.67
L-index

#	Paper	IF	Citations
92	Metabolomic and inflammatory signatures of symptom dimensions in major depression.. <i>Brain, Behavior, and Immunity</i> , 2022 , 102, 42-52	16.6	1
91	Bile acid synthesis, modulation, and dementia: A metabolomic, transcriptomic, and pharmacoepidemiologic study. <i>PLoS Medicine</i> , 2021 , 18, e1003615	11.6	10
90	Serum metabolites associated with brain amyloid beta deposition, cognition and dementia progression. <i>Brain Communications</i> , 2021 , 3, fcab139	4.5	1
89	Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. <i>Translational Psychiatry</i> , 2021 , 11, 153	8.6	16
88	Sex and APOE ϵ genotype modify the Alzheimer's disease serum metabolome. <i>Nature Communications</i> , 2020 , 11, 1148	17.4	46
87	Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. <i>Journal of Affective Disorders</i> , 2020 , 264, 90-97	6.6	16
86	Gut microbial molecules in behavioural and neurodegenerative conditions. <i>Nature Reviews Neuroscience</i> , 2020 , 21, 717-731	13.5	67
85	Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease. <i>Nature Communications</i> , 2020 , 11, 5698	17.4	23
84	Peripheral serum metabolomic profiles inform central cognitive impairment. <i>Scientific Reports</i> , 2020 , 10, 14059	4.9	8
83	Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. <i>Translational Psychiatry</i> , 2019 , 9, 173	8.6	34
82	Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts. <i>Scientific Data</i> , 2019 , 6, 212	8.2	6
81	Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. <i>Biochemical Pharmacology</i> , 2018 , 152, 279-292	6	23
80	Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. <i>Translational Psychiatry</i> , 2018 , 8, 10	8.6	32
79	The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 81, 55-63	5.5	28
78	Augmentation of Physician Assessments with Multi-Omics Enhances Predictability of Drug Response: A Case Study of Major Depressive Disorder. <i>IEEE Computational Intelligence Magazine</i> , 2018 , 13, 20-31	5.6	16
77	Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. <i>PLoS Medicine</i> , 2018 , 15, e1002482	11.6	187
76	Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018 , 7, 525-533	4.5	10

75	Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. <i>Journal of Affective Disorders</i> , 2018 , 238, 1-7	6.6	17
74	Ketamine potentiates oxidative stress and influences behavior and inflammation in response to lipolysaccharide (LPS) exposure in early life. <i>Neuroscience</i> , 2017 , 353, 17-25	3.9	28
73	Metabolic network failures in Alzheimer's disease: A biochemical road map. <i>Alzheimer's and Dementia</i> , 2017 , 13, 965-984	1.2	201
72	Pharmacometabolomic signature links simvastatin therapy and insulin resistance. <i>Metabolomics</i> , 2017 , 13, 1	4.7	10
71	The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback. <i>Translational Psychiatry</i> , 2017 , 7, e1193	8.6	15
70	Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. <i>Translational Psychiatry</i> , 2016 , 6, e894	8.6	55
69	TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. <i>Molecular Psychiatry</i> , 2016 , 21, 1717-1725	15.1	71
68	Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians. <i>Journal of Alzheimer's Disease</i> , 2016 , 49, 991-1003	4.3	10
67	Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans. <i>Frontiers in Pharmacology</i> , 2016 , 7, 135	5.6	20
66	A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration. <i>Hypertension</i> , 2016 , 68, 621-9	8.5	18
65	Metabolomics enables precision medicine: "A White Paper, Community Perspective". <i>Metabolomics</i> , 2016 , 12, 149	4.7	327
64	Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics. <i>Pharmacogenomics</i> , 2015 , 16, 649-65	2.6	18
63	Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2015 , 98, 71-5	6.1	115
62	Oxylipid Profile of Low-Dose Aspirin Exposure: A Pharmacometabolomics Study. <i>Journal of the American Heart Association</i> , 2015 , 4, e002203	6	15
61	Associations between central nervous system serotonin, fasting glucose, and hostility in African American females. <i>Annals of Behavioral Medicine</i> , 2015 , 49, 49-57	4.5	6
60	Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015 , 4, 669-79	4.5	26
59	O4-12-06: The Alzheimer's metabolome: Identification of novel markers and treatment targets 2015 , 11, P301-P302		
58	Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review. <i>Metabolomics</i> , 2015 , 11, 872-894	4.7	171

57	Module-based association analysis for omics data with network structure. <i>PLoS ONE</i> , 2015 , 10, e0122309	3.7	4
56	Quality assurance of metabolomics. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2015 , 32, 319-26	4.3	26
55	Is diabetes mellitus-linked amino acid signature associated with β -blocker-induced impaired fasting glucose?. <i>Circulation: Cardiovascular Genetics</i> , 2014 , 7, 199-205		19
54	Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2014 , 3, e125	4.5	42
53	Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 154-67	6.1	138
52	Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging. <i>Acta Neuropathologica Communications</i> , 2013 , 1, 28	7.3	42
51	Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 570-3	6.1	28
50	Pharmacometabolomics of statin response. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 562-5	6.1	37
49	Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 525-32	6.1	60
48	Alterations in metabolic pathways and networks in Alzheimer's disease. <i>Translational Psychiatry</i> , 2013 , 3, e244	8.6	129
47	Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. <i>Translational Psychiatry</i> , 2013 , 3, e223	8.6	66
46	Pharmacometabolomics reveals racial differences in response to atenolol treatment. <i>PLoS ONE</i> , 2013 , 8, e57639	3.7	59
45	Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. <i>PLoS ONE</i> , 2013 , 8, e68283	3.7	62
44	Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. <i>PLoS ONE</i> , 2013 , 8, e68717	3.7	75
43	Pharmacometabolomic signature of ataxia SCA1 mouse model and lithium effects. <i>PLoS ONE</i> , 2013 , 8, e70610	3.7	11
42	Associations between purine metabolites and monoamine neurotransmitters in first-episode psychosis. <i>Frontiers in Cellular Neuroscience</i> , 2013 , 7, 90	6.1	21
41	Plasma omega-3 polyunsaturated fatty acids and survival in patients with chronic heart failure and major depressive disorder. <i>Journal of Cardiovascular Translational Research</i> , 2012 , 5, 92-9	3.3	24
40	Impaired plasmalogens in patients with schizophrenia. <i>Psychiatry Research</i> , 2012 , 198, 347-52	9.9	54

39	Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. <i>PLoS ONE</i> , 2012 , 7, e38386	3.7	76
38	Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile. <i>Scientific Reports</i> , 2012 , 2, 667	4.9	56
37	3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2011 , 14, 756-67	5.8	63
36	Metabolomic changes in autopsy-confirmed Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011 , 7, 309-17	10.5	
35	Enteric microbiome metabolites correlate with response to simvastatin treatment. <i>PLoS ONE</i> , 2011 , 6, e25482	3.7	127
34	Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 97-104	6.1	125
33	Pretreatment metabolite as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. <i>Translational Psychiatry</i> , 2011 , 1,	8.6	90
32	Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. <i>PLoS ONE</i> , 2011 , 6, e21643	3.7	284
31	Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. <i>Molecular Psychiatry</i> , 2010 , 15, 938-53	15.1	76
30	Metabolomic differences in heart failure patients with and without major depression. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2010 , 23, 138-46	3.8	50
29	Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. <i>Metabolomics</i> , 2010 , 6, 191-201	4.7	86
28	Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions. <i>Metabolomics</i> , 2010 , 6, 165-179	4.7	53
27	Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naive patients with schizophrenia. <i>PLoS ONE</i> , 2010 , 5, e9508	3.7	53
26	Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. <i>Neurobiology of Disease</i> , 2009 , 35, 165-76	7.5	215
25	Opioid use affects antioxidant activity and purine metabolism: preliminary results. <i>Human Psychopharmacology</i> , 2009 , 24, 666-75	2.3	45
24	Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study. <i>Psychopharmacology</i> , 2009 , 206, 479-89	4.7	56
23	Metabolomics: a global biochemical approach to the study of central nervous system diseases. <i>Neuropsychopharmacology</i> , 2009 , 34, 173-86	8.7	208
22	Metabolomics: a global biochemical approach to drug response and disease. <i>Annual Review of Pharmacology and Toxicology</i> , 2008 , 48, 653-83	17.9	517

21	The metabolomics standards initiative. <i>Nature Biotechnology</i> , 2007 , 25, 846-8	44.5	253
20	Metabolomic mapping of atypical antipsychotic effects in schizophrenia. <i>Molecular Psychiatry</i> , 2007 , 12, 934-45	15.1	206
19	Metabolic profiling of patients with schizophrenia. <i>PLoS Medicine</i> , 2006 , 3, e363	11.6	32
18	Metabolomics Standards Workshop and the development of international standards for reporting metabolomics experimental results. <i>Briefings in Bioinformatics</i> , 2006 , 7, 159-65	13.4	68
17	Establishing reporting standards for metabolomic and metabonomic studies: a call for participation. <i>OMICS A Journal of Integrative Biology</i> , 2006 , 10, 158-63	3.8	87
16	Biomarkers for amyotrophic lateral sclerosis. <i>Expert Review of Molecular Diagnostics</i> , 2006 , 6, 387-98	3.8	40
15	Metabolomic analysis and signatures in motor neuron disease. <i>Metabolomics</i> , 2005 , 1, 101-108	4.7	130
14	Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. <i>Journal of Neurochemistry</i> , 2001 , 77, 383-90	6	100
13	Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. <i>Journal of Neuroscience</i> , 2000 , 20, 4389-97	6.6	454
12	Amyotrophic lateral sclerosis: Transgenic model and novel neuroprotective agent. <i>Neuroscience Research Communications</i> , 2000 , 26, 215-226		1
11	Neuroprotective effects of creatine administration against NMDA and malonate toxicity. <i>Brain Research</i> , 2000 , 860, 195-8	3.7	62
10	Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. <i>Nature Medicine</i> , 1999 , 5, 347-50	50.5	611
9	Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. <i>Journal of Neuroscience</i> , 1998 , 18, 156-63	6.6	365
8	Synthesis and creatine kinase inhibitory activity of non-hydrolyzable analogs of phosphocreatine. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1997 , 7, 1021-1026	2.9	5
7	Depletion of energy reserve via the creatine kinase reaction during the evolution of heart failure in cardiomyopathic hamsters. <i>Journal of Molecular and Cellular Cardiology</i> , 1996 , 28, 755-65	5.8	92
6	Enhancement of cardiac function by cyclocreatine in models of cardiopulmonary bypass. <i>Journal of Molecular and Cellular Cardiology</i> , 1995 , 27, 1065-73	5.8	6
5	Cyclocreatine in cancer chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 35, 411-6	3.5	25
4	Microtubule stabilization and potentiation of taxol activity by the creatine analog cyclocreatine. <i>Anti-Cancer Drugs</i> , 1995 , 6, 419-26	2.4	10

3	Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits the replication of human herpes viruses. <i>Antiviral Research</i> , 1994 , 23, 203-18	10.8	11
2	Enhancement of the recovery of rat hearts after prolonged cold storage by cyclocreatine phosphate. <i>Transplantation</i> , 1994 , 57, 803-6	1.8	11
1	Activation and repression of mammalian gene expression by the c-myc protein. <i>Genes and Development</i> , 1987 , 1, 347-57	12.6	135